In Brief: InStent
This article was originally published in The Gray Sheet
InStent: Receives conditional approval of an investigational device exemption to begin human clinical trials of its self-expanding, nitinol CardioCoil coronary stent in reducing restenosis following angioplasty. "Conditions set forth in the approval letter from the FDA will be addressed by the company in the very near future," the firm says...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.